In many countries (e.g., Australia, the UK, and Russia) it is commonly used for major depressive disorder.<unk>  is also approved in the United States for OCD, and social anxiety disorder. In Japan it is also approved to treat OCD, social anxiety disorder and MDD.<unk>  is indicated for children and adolescents with OCD. The drug works long-term, and retains its therapeutic efficacy for at least one year. It has also been found to possess some analgesic properties in line with other SSRIs and tricyclic antidepressants. There is tentative evidence that<unk>  is effective for social phobia in adults.<unk>  is also effective for GAD, social anxiety disorder, panic disorder and separation anxiety disorder in children and adolescents. There is tentative evidence that<unk>  may help some people with negative symptoms of chronic schizophrenia. There is tentative evidence<unk>  might be useful for reducing COVID-19 disease severity if given as an early treatment. In the US as of January 2022, the National Institutes of Health panel had said the evidence was inconclusive and the Food and Drug Administration were considering a request for emergency use. In Canada, Ontario's COVID-19 Advisory had approved it for usage if other preferred treatments were unavailable.
Fluvoxamine
Medifoxamine
Phentermine
Gepirone
Pheniramine
Mephentermine
Doxepin
Sertindole